Study summary · research use only
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This rat study examined whether the growth hormone secretagogue ipamorelin altered glucocorticoid-induced changes in muscle and bone in adult female rats. Rats received subcutaneous glucocorticoid (methylprednisolone), ipamorelin, or both for 3 months. In animals given both together, maximum tetanic calf muscle tension was reported to increase significantly, and periosteal bone formation rate increased four-fold, compared with glucocorticoid alone. The authors reported that combined administration counteracted the decreases in muscle strength and bone formation seen with glucocorticoid alone.
Abstract
The ability of the growth hormone secretagogue (GHS) Ipamorelin to counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone was investigated in vivo in an adult rat model. Groups of 8-month-old female rats were injected subcutaneously for 3 months with GC (methylprednisolone) 9 mg/kg/day or GHS (Ipamorelin) 100 microg/kg three times daily, or both GC and GHS in combination. The maximum tetanic tension of the calf muscles was determined in vivo in a materials testing machine. The maximum tetanic tension was increased significantly, and the periosteal bone formation rate increased four-fold in animals injected with GC and GHS in combination, compared with the group injected with GC alone. In conclusion, the decrease in muscle strength and bone formation found in GC-injected rats was counteracted by simultaneous administration of the growth hormone secretagogue.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.